Proliferative nodules arising within congenital melanocytic nevi: A histologic, immunohistochemical, and molecular analyses of 43 cases

American Journal of Surgical Pathology

Volumn 35, Issue 5, 2011, Pages 656-669

  Phadke, Pushkar A ^a   Rakheja, Dinesh ^b   Le, Long P ^a   Selim, Maria Angelica ^c   Kapur, Payal ^b   Davis, Amy ^b   Mihm Jr , Martin C ^a   Hoang, Mai P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

congenital nevi; immunohistochemistry; mutational analyses; Proliferative nodule

Indexed keywords

GNAQ PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; KI 67 ANTIGEN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CHILD; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MELANOMA; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; PIGMENTED NEVUS; PRESCHOOL CHILD; SKIN TUMOR;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RAS PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79954977778     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31821375ea     Document Type: Article

References (48)

1. Alper JC, Holmes LB. The incidence and significance ofbirthmarks in a cohort of 4641 newborns. Pediatr Dermatol. 1983;1:58-68. (Pubitemid 14152412)
2. Bastian BC, Xiong J, Frieden IJ, et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol. 2002;161:1163-1169.
3. Bauer J, Curtin JA, Pinkel D, et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007;127:179-182. (Pubitemid 46005676)
4. Bergman R, Malkin L, Sabo E, et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol. 2001;44:500-504. (Pubitemid 32199972)
5. Bittencourt FV, Marghoob AA, Kopf AW, et al. Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis. Pediatrics. 2000; 106:736-741.
6. Bolande RP. The neurocristopathies: a unifying concept of disease arising in neural crest development. Hum Pathol. 1974;5:409-429.
7. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignantmelanomaandcongenitalnaevi. Br J Dermatol. 1994;131: 72-77. (Pubitemid 24234291)
8. Collina G, Deen S, Cliff S, et al. Atypical dermal nodules in benign melanocytic naevi. Histopathology. 1997;31:97-101. (Pubitemid 27314513)
9. Crowson AN, Magro CM, Mihm MC. The Melanocytic Prolifera-tions: A Comprehensive Textbook of Pigmented Lesions. New York: Wiley-Liss; 2001.
10. Davies H, Bignell GR, Cox C, et al. Mutations ofthe BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
11. De Raeve LE, Claes A, Ruiter DJ, et al. Distinct phenotypic changes between the superficial and deep component of giant congenital melanocytic nevi: a rationale for curettage. Br J Dermatol. 2006;154: 485-492. (Pubitemid 43382657)
12. Dessars B, De Raeve LE, El Housni H, et al. Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J Invest Dermatol. 2007;127: 1468-1470. (Pubitemid 46762984)
13. Dessars B, De Raeve LE, Morandini R, et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol. 2009;129: 139-147.
14. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146-158.
15. Elder DE, Murphy GF. Atlas of Tumor Pathology: Melanocytic Tumors of the Skin. Washington, DC: Armed Forces Institute of Pathology; 1991.
16. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715. (Pubitemid 14035254)
17. Gurley LR, D'Anna JA, Barham SS, et al. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem. 1978;84:1-15. (Pubitemid 8286682)
18. Hendrickson MR, Ross JC. Neoplasms arising in congenital giant nevi: morphologic study ofseven cases and a review ofthe literature. Am J Surg Pathol. 1981;5:109-135. (Pubitemid 11114085)
19. Herron MD, Vanderhooft SL, Smock K, et al. Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohis-tochemical analysis. Am J Surg Pathol. 2004;28:1017-1025. (Pubitemid 38971425)
20. Huang S, Jean D, Luca M, et al. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumor-igenicity and metastasis. EMBO J. 1998;17:4358-4369. (Pubitemid 28362626)
21. Ichii-Nakato N, Takata M, Takayanagi S, et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol. 2006;126:2111-2118.
22. Jerdan MS, Smith RRL, Cohen BA, et al. Neuroectodermal neo-plasms arising in congenital nevi. Am J Dermatopathol. 1985;7:41-48.
23. Kanter-Lewensohn L, Hedblad MA, Wejde J, et al. Immunohisto-chemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol. 1997;10:917-920. (Pubitemid 27431966)
24. Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol. 2005;18:197-204. (Pubitemid 40188626)
25. Kuwata T, Kitagawa M, Kusaga T. Proliferative activity ofprimary cutaneous melanocytic tumors. Virchows Arch A Pathol Anat Histopathol. 1993;423:359-364. (Pubitemid 23345710)
26. Leech SN, Bell H, Leonard N, et al. Neonatal giant congenital nevi with proliferative nodules: a clinicopathologic study and literature review ofneonatal melanoma. Arch Dermatol. 2004;140:83-88. (Pubitemid 38090274)
27. Lowes MA, Norris D, Whitfeld M. Benign melanocytic proliferative nodule within a congenital nevus. Australas J Dermatol. 2000;41: 109-111. (Pubitemid 30304006)
28. Luo R, Gao J, Wehrle-Haller B, et al. Molecular identification of distinct neurogenic and melanogenic neural crest sublineages. Development. 2003;130:321-330. (Pubitemid 36175930)
29. Magro CM, Crowson AN, Mihm MC Jr, et al. The dermal-based borderline melanocytic tumor: a categorical approach. J Am Acad Dermatol. 2010;62:469-479.
30. Mancianti ML, Clark WH, Hayes FA, et al. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol. 1990;136:817-829. (Pubitemid 20142318)
31. Nasr MR, El-Zammar O. Comparison of PHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122. (Pubitemid 351441982)
32. Ohashi A, Funasaka Y, Ueda M, et al. c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic nevi. Melanoma Res. 1996;6:25-30. (Pubitemid 26065018)
33. Papp T, Pemsel H, Zimmermann R, et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet. 1999;36: 610-614. (Pubitemid 29368901)
34. Papp T, Schipper H, Kumar K, et al. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic nevi. Melanoma Res. 2005;15:401-407. (Pubitemid 41558950)
35. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20. (Pubitemid 36068675)
36. Reed RJ, Ichinose H, Clark WH Jr, et al. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol. 1975;2: 119-147.
37. Richardson SK, Tannous ZS, Mihm MC Jr. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol. 2002;47:77-90.
38. Ruiz-Maldonado R, Tamayo L, Laterza AM, et al. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr. 1992;120:906-911.
39. Stafanaki C, Stafanaki K, Antoniou C, et al. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas. J Cutan Pathol. 2008;35:799-808.
40. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89. (Pubitemid 43740213)
41. Torres-Cabala CA, Wang W-L, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009;22:1446-1456.
42. Van Houten AH, van Dijk MC, Schuttelaar ML. Proliferative nodules in a giant congenital melanocytic nevus-case report and review ofthe literature. J Cutan Pathol. 2010;37:764-776.
43. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599-603.
44. Xu X, Bellucci KS, Elenitsas R, et al. Cellular nodules in congenital pattern nevi. J Cutan Pathol. 2004;31:153-159. (Pubitemid 38130425)
45. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations ofthe BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003;121:1160-1162. (Pubitemid 37430987)
46. Yoshida H, Kunisada T, Grimm T, et al. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc. 2001;6:1-5. (Pubitemid 33758596)
47. Wehrle-Haller B. The role of kit-ligand in melanocyte develop-ment and epidermal homeostasis. Pigment Cell Res. 2003;16: 287-296. (Pubitemid 36597070)
48. Wu J, Rosenbaum E, Begum S, et al. Distribution ofBRAFT1799A (V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol. 2007;29: 534-537. (Pubitemid 350158863)